MA55705A - Anticorps bispécifiques - Google Patents

Anticorps bispécifiques

Info

Publication number
MA55705A
MA55705A MA055705A MA55705A MA55705A MA 55705 A MA55705 A MA 55705A MA 055705 A MA055705 A MA 055705A MA 55705 A MA55705 A MA 55705A MA 55705 A MA55705 A MA 55705A
Authority
MA
Morocco
Prior art keywords
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA055705A
Other languages
English (en)
Inventor
Jens Breinholt
Prafull S Gandhi
Henrik Østergaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA55705A publication Critical patent/MA55705A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055705A 2019-04-17 2020-04-15 Anticorps bispécifiques MA55705A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19169704 2019-04-17
EP19213867 2019-12-05

Publications (1)

Publication Number Publication Date
MA55705A true MA55705A (fr) 2022-02-23

Family

ID=70189980

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055705A MA55705A (fr) 2019-04-17 2020-04-15 Anticorps bispécifiques

Country Status (15)

Country Link
US (2) US11325983B2 (fr)
EP (1) EP3956359A1 (fr)
JP (2) JP7297928B2 (fr)
KR (2) KR102652906B1 (fr)
CN (1) CN113692415A (fr)
AU (1) AU2020259982A1 (fr)
BR (1) BR112021019959A2 (fr)
CA (1) CA3135632A1 (fr)
CL (1) CL2021002710A1 (fr)
CO (1) CO2021014072A2 (fr)
IL (1) IL286757A (fr)
MA (1) MA55705A (fr)
MX (1) MX2021012365A (fr)
PE (1) PE20212262A1 (fr)
WO (1) WO2020212415A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102652906B1 (ko) * 2019-04-17 2024-04-01 노보 노르디스크 에이/에스 이중 특이적 항체
EP4227430A4 (fr) 2020-10-12 2024-03-27 Nippon Steel Corporation Tôle d'acier galvanisée à chaud au trempé
AU2023216348A1 (en) * 2022-02-03 2024-06-20 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541275B1 (en) 1988-02-03 2003-04-01 Dade Behring Inc. Immunoassay for F1.2 prothrombin fragment
TW212184B (fr) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH05168494A (ja) 1991-05-17 1993-07-02 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
WO1996001653A1 (fr) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Procedes et compositions pour la coagulation specifique de vaisseaux
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
US20040180409A1 (en) 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
DE10354403A1 (de) 2003-11-20 2005-06-23 Dade Behring Marburg Gmbh Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
WO2007115953A1 (fr) 2006-04-07 2007-10-18 Novo Nordisk Health Care Ag Complexe covalent du facteur vii et du facteur tissulaire
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
CN104059155A (zh) 2008-05-16 2014-09-24 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2010132370A2 (fr) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptides solubles de la famille trem-1 et procédés d'utilisation
EP2470561A1 (fr) 2009-08-27 2012-07-04 Novo Nordisk A/S Ciblage du facteur tissulaire sur des plaquettes activées
ES2805301T3 (es) 2010-04-08 2021-02-11 Inst Nat Sante Rech Med Péptidos inhibidores derivados del transcrito de tipo TREM-1 (TLT-1) y sus usos
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
EP2644698B1 (fr) 2010-11-17 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à un antigène multi-spécifique ayant une fonction alternative par rapport à la fonction du facteur viii de coagulation sanguine
EP2680875B1 (fr) 2011-03-02 2019-10-23 Novo Nordisk Health Care AG Facteur de coagulation ciblant tlt-1 sur des plaquettes activées
CN110023339A (zh) 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
KR102652906B1 (ko) * 2019-04-17 2024-04-01 노보 노르디스크 에이/에스 이중 특이적 항체

Also Published As

Publication number Publication date
US20220064329A1 (en) 2022-03-03
CN113692415A (zh) 2021-11-23
CL2021002710A1 (es) 2022-05-27
KR102652906B1 (ko) 2024-04-01
JP2023116676A (ja) 2023-08-22
US20220213218A1 (en) 2022-07-07
CO2021014072A2 (es) 2022-01-17
WO2020212415A1 (fr) 2020-10-22
JP7297928B2 (ja) 2023-06-26
MX2021012365A (es) 2021-11-17
PE20212262A1 (es) 2021-11-29
US11325983B2 (en) 2022-05-10
BR112021019959A2 (pt) 2022-02-08
IL286757A (en) 2021-10-31
EP3956359A1 (fr) 2022-02-23
JP2022529036A (ja) 2022-06-16
AU2020259982A1 (en) 2021-10-28
CA3135632A1 (fr) 2020-10-22
KR20240046282A (ko) 2024-04-08
KR20210153639A (ko) 2021-12-17

Similar Documents

Publication Publication Date Title
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
MA55363A (fr) Anticorps multispécifiques egfr x cd28
MA45255A (fr) Anticorps inhibiteurs de points de contrôle bispécifiques
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA46057A (fr) Anticorps anti-ctla4
MA52366A (fr) Anticorps anti-tl1a optimisés
MA50352A (fr) Anticorps multispécifiques
MA52212A (fr) Anticorps multivalent
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52152A (fr) Anticorps
MA49749A (fr) Anticorps anti-cd137
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA53905A (fr) Anticorps stabilisant trem2
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
MA49250A (fr) Nouveaux anticorps anti-cd3
MA51134A (fr) Anticorps anti-alpha-synucléine
MA55705A (fr) Anticorps bispécifiques